GlassScriptPhysician profile
Jill Steier
NPI 1033103551
$3,944.62
in general payments reported to CMS, 2019-2025
31 companies · $27.05 in 2025
The $27.05 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $349 · 2021: $642 · 2022: $970 · 2023: $1,040 · 2024: $240 · 2025: $27.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.14 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $625.64 | 2021-2024 | Ova1 |
| Abbvie INC. | $550.61 | 2019-2024 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $455.03 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $311.32 | 2019-2024 | |
| Exeltis, USA INC. | $205.36 | 2020-2023 | Slynd |
| Therapeuticsmd, INC. | $149.60 | 2020-2022 | |
| Organon LLC | $144.23 | 2021-2024 | Nexplanon |
| Avanos Medical | $136.47 | 2019 | |
| Mylan Pharmaceuticals INC. | $132.25 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.79 | 2019-2023 | |
| Myriad Women'S Health, INC. | $119.77 | 2023 | Myrisk |
| Agile Therapeutics, INC. | $113.24 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $109.69 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $83.41 | 2019-2020 | |
| Coopersurgical, INC. | $76.89 | 2019-2023 | Mara Console |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $75.99 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $75.32 | 2019-2020 | |
| Millicent US INC | $71.57 | 2022-2023 | Intrarosa, Femring |
| Hologic Sales and Service, LLC | $56.82 | 2021-2025 | Aptima |
| Allergan, INC. | $56.08 | 2019 | |
| Medtronic, INC. | $41.53 | 2022-2023 | Truclear |
| Biogen, INC. | $38.69 | 2024 | |
| Lupin INC. | $37.92 | 2019-2020 | |
| Duchesnay USA Incorporated | $28.94 | 2019 | |
| Myovant Sciences INC. | $25.97 | 2022 | |
| Avion Pharmaceuticals | $24.60 | 2019-2021 | |
| Daiichi Sankyo INC. | $21.23 | 2019 | |
| Shield Therapeutics INC | $16.16 | 2023 | |
| Conmed Corporation | $15.02 | 2019 | |
| Intuitive Surgical, INC. | $12.99 | 2019 | |
| Evofem Biosciences, INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Steier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.